The oncology blood testing market is projected to grow from USD 5.9 billion in 2025 to USD 24.2 billion by 2035, at a CAGR of 15.2%. Liquid Biopsy Assays will dominate with a 31.6% market share, while lung cancer will lead the application segment with a 29.4% share.